This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: [email protected].
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/q4-1-jan-to-31-mar-2024-annb-and-ypa-screening-kpi-data/antenatal-and-newborn-screening-kpi-data-q4-summary-factsheets-1-january-to-31-march-2024
This report should be read in conjunction with the full KPI data tables published each quarter.
1. Fetal anomaly screening
1.1
KPI FA2: coverage: fetal anomaly ultrasound
National performance of FA2 (see standard FASP-SO2) in quarter 3 2023 to 2024 was 98.6%. FA2 is collected 6 months (2 quarters) in arrears.
Quarter 3 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 3 2023 to 2024
131,157
133,014
98.6%
Region
Performance %
East of England
99.2%
London
97.8%
Midlands
98.7%
North East and Yorkshire
99.0%
North West
99.0%
South East
98.4%
South West
98.6%
England
98.6%
1.2
KPI FA3
There is no intention to publish FA3 (see standard FASP-S01) by individual maternity service.
1.3
KPI FA4: combined samples
FA4 (see standard FASP-SO6) was introduced in 2020 to 2021. New KPIs are not published in the first year of data collection. This time is used to improve the data quality and completeness, by revising the definition, adding clarity and / or setting thresholds as required.
In quarter 4 2023 to 2024, national performance of FA4 for inadequate combined samples was 3.8%. FA4 is a KPI where a lower performance is better.
Quarter 4 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 4 2023 to 2024
4,091
107,126
3.8%
Region
Performance %
East of England
2.9%
London
1.3%
Midlands
4.6%
North East and Yorkshire
6.3%
North West
4.4%
South East
4.5%
South West
3.1%
England
3.8%
1.4
KPI FA4: quadruple samples
FA4 (see standard FASP-SO6) was introduced in 2020 to 2021. New KPIs are not published in the first year of data collection. This time is used to improve the data quality and completeness, by revising the definition, adding clarity and / or setting thresholds as required.
In quarter 4 2023 to 2024, national performance of FA4 for inadequate quadruple samples was 7.8%. FA4 is a KPI where a lower performance is better.
Quarter 4 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 4 2023 to 2024
1,089
13,963
7.8%
Region
Performance %
East of England
5.9%
London
3.1%
Midlands
6.5%
North East and Yorkshire
13.5%
North West
6.1%
South East
11.5%
South West
18.5%
England
7.8%
2. Infectious diseases in pregnancy screening
2.1
KPI ID1: HIV coverage
National performance of ID1 (see standard IDPS-S01) in quarter 4 2023 to 2024 was 99.8%.
Quarter 4 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 4 2023 to 2024
162,069
162,371
99.8%
Region
Performance %
East of England
99.8%
London
99.9%
Midlands
99.8%
North East and Yorkshire
99.8%
North West
99.8%
South East
99.8%
South West
99.6%
England
99.8%
2.2
KPI ID2: diagnosis/intervention: timely assessment of women with hepatitis B
National performance of ID2 (see standard IDPS-S06) in quarter 4 2023 to 2024 was 71.9%. The submission of data for ID2 has changed in 2023 to 2024 from maternity service self-reporting to the Integrated Screening Outcomes Surveillance Service (ISOSS) to improve consistency and accuracy of data returns. This has led to an expected reduction in performance as a result of more accurate data, and does not reflect a change in practice for screening providers.
ID2 is a small number KPI, therefore the data should be interpreted with caution.
Quarter 4 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 4 2023 to 2024
110
153
71.9%
Region
Performance %
East of England
66.7%
London
79.5%
Midlands
66.7%
North East and Yorkshire
65.2%
North West
81.2%
South East
78.6%
South West
61.5%
England
71.9%
2.3
KPI ID3: coverage: hepatitis B
National performance of ID3 (see standard IDPS-S02) in quarter 4 2023 to 2024 was 99.8%.
Quarter 4 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 4 2023 to 2024
162,067
162,362
99.8%
Region
Performance %
East of England
99.8%
London
99.9%
Midlands
99.8%
North East and Yorkshire
99.8%
North West
99.8%
South East
99.8%
South West
99.6%
England
99.8%
2.4
KPI ID4: coverage: syphilis
National performance of ID4 (see standard IDPS-S03) in quarter 4 2023 to 2024 was 99.8%.
Quarter 4 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 4 2023 to 2024
162,063
162,359
99.8%
Region
Performance %
East of England
99.8%
London
99.9%
Midlands
99.8%
North East and Yorkshire
99.8%
North West
99.8%
South East
99.8%
South West
99.6%
England
99.8%
3. Sickle cell and thalassaemia screening
3.1
KPI ST1: coverage: antenatal screening
National performance of ST1 (see standard SCT-S01) in quarter 4 2023 to 2024 was 99.8%.
Quarter 4 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 4 2023 to 2024
161,894
162,240
99.8%
Region
Performance %
East of England
99.8%
London
99.9%
Midlands
99.7%
North East and Yorkshire
99.8%
North West
99.8%
South East
99.8%
South West
99.6%
England
99.8%
3.2
KPI ST2: test: timeliness of antenatal screening
National performance of ST2 (see standard SCT-S02) in quarter 4 2023 to 2024 was 61.2%.
Quarter 4 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 4 2023 to 2024
100,283
163,885
61.2%
Region
Performance %
East of England
65.9%
London
54.6%
Midlands
56.6%
North East and Yorkshire
70.6%
North West
60.4%
South East
62.5%
South West
64.8%
England
61.2%
3.3
KPI ST3: test: completion of family origin questionnaire (FOQ)
National performance of ST3 (see standard SCT-S03) in quarter 4 2023 to 2024 was 97.9%.
Quarter 4 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 4 2023 to 2024
161,131
164,507
97.9%
Region
Performance %
East of England
97.8%
London
99.7%
Midlands
96.4%
North East and Yorkshire
98.0%
North West
97.8%
South East
97.5%
South West
98.0%
England
97.9%
3.4
KPI ST4a: referral: timely offer of prenatal diagnosis (PND) to women at risk of having an infant with sickle cell disease or thalassaemia
National performance of ST4a (see standard SCT-S05) in quarter 4 2023 to 2024 was 48.7%. Thresholds have not yet been set for this KPI.
ST4a is a small number KPI, therefore the data should be interpreted with caution.
Quarter 4 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 4 2023 to 2024
287
589
48.7%
Region
Performance %
East of England
72.1%
London
46.8%
Midlands
48.3%
North East and Yorkshire
56.0%
North West
19.4%
South East
44.8%
South West
20.0%
England
48.7%
3.5
KPI ST4b: referral: timely offer of prenatal diagnosis (PND) to couples at risk of having an infant with sickle cell disease or thalassaemia
National performance of ST4b (see standard STC-S05) in quarter 4 2023 to 2024 was 62.6%. Thresholds have not yet been set for this KPI.
ST4b is a small number KPI, therefore the data should be interpreted with caution.
Quarter 4 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 4 2023 to 2024
244
390
62.6%
Region
Performance %
East of England
71.8%
London
74.8%
Midlands
56.6%
North East and Yorkshire
62.7%
North West
35.0%
South East
54.8%
South West
61.1%
England
62.6%
4. Newborn blood spot screening
4.1
KPI NB1: coverage of CCG responsibility at birth
National performance of NB1 (see standard NBS-S01a) in quarter 4 2023 to 2024 was 97.0%.
Quarter 4 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 4 2023 to 2024
120,444
124,150
97.0%
Region
Performance %
East of England
99.6%
London
95.6%
Midlands
96.9%
North East and Yorkshire
98.0%
North West
96.0%
South East
97.7%
South West
95.8%
England
97.0%
4.2
KPI NB2: test: quality of the blood spot sample
National performance of NB2 (see standard NBS-S06) in quarter 4 2023 to 2024 was 2.8%.
Quarter 4 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 4 2023 to 2024
3,770
136,313
2.8%
Region
Performance %
East of England
2.0%
London
2.2%
Midlands
2.9%
North East and Yorkshire
2.9%
North West
3.3%
South East
3.4%
South West
2.7%
England
2.8%
4.3
KPI NB4: coverage of movers in
National performance of NB4 (see standard NBS-S01b) in quarter 4 2023 to 2024 was 80.2%.
Quarter 4 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 4 2023 to 2024
9,223
11,505
80.2%
Region
Performance %
East of England
85.1%
London
70.5%
Midlands
78.7%
North East and Yorkshire
89.0%
North West
82.7%
South East
83.8%
South West
80.7%
England
80.2%
5. Newborn hearing screening
5.1
KPI NH1: coverage
National performance of NH1 (see standard NHSP-S01) in quarter 4 2023 to 2024 was 99.1%.
Quarter 4 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 4 2023 to 2024
147,514
148,887
99.1%
Region
Performance %
East of England
99.2%
London
98.8%
Midlands
99.1%
North East and Yorkshire
99.1%
North West
98.8%
South East
99.5%
South West
99.1%
England
99.1%
5.2
KPI NH2: diagnosis/intervention – time from screening outcome to attendance at an audiological assessment appointment
National performance of NH2 (see standard NHSP-S05) in quarter 4 2023 to 2024 was 90.1%.
Quarter 4 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 4 2023 to 2024
10,307
11,443
90.1%
Region
Performance %
East of England
88.5%
London
91.1%
Midlands
90.3%
North East and Yorkshire
89.4%
North West
87.5%
South East
92.2%
South West
93.2%
England
90.1%
6. Newborn and infant physical examination screening
6.1
KPI NP1: coverage
National performance of NP1 (see standard NIPE-S01) in quarter 4 2023 to 2024 was 96.4%.
Quarter 4 performance
Reporting period
Numerator
Denominator
Performance %
Quarter 4 2023 to 2024
135,350
140,425
96.4%
Region
Performance %
East of England
96.9%
London
96.1%
Midlands
96.3%
North East and Yorkshire
96.6%
North West
96.2%
South East
95.8%
South West
97.6%
England
96.4%
6.2
KPI NP3: diagnosis/intervention – timeliness of ultrasound scan of the hips for developmental dysplasia
NP3 (see standard NIPE-S03) was introduced in 2021 to 2022. New KPIs are not published in the first year of data collection. This time is used to improve the data quality and completeness, by revising the definition, adding clarity and / or setting thresholds as required.
In quarter 4 2023 to 2024, national performance of NP3 was 76.2%.
